Op-eds: Canadian and American regulators, law enforcement and patient advocates oppose drug importation
Since 2000, every head of the United States Food and Drug Administration (FDA) and United States Department of Health and Human Services (HHS) has opposed drug importation because the benefits that might be gained are far outweighed by the many dangers. Law enforcement, patient advocates, pharmacy groups, and regulators agree.
Counterfeiting of drugs has exploded since we last had a serious debate about the importation of branded drugs. In just one year, 2013, the Pharmaceutical Security Institute reports that worldwide incidents of pharmaceutical crime rose almost 9%. During one week in 2013, the FDA, in partnership with Interpol, seized $41 million worth of illegal or counterfeit medicines, and shut down over 1,600 illegal online pharmacies. Mexico is a major global source of those fake drugs. Its illicit trade stands at an estimated $650 million per year–equal to 10% of its total drug sales.
In 2016, The Canadian Arthritis Patient Alliance wrote a letter asking American “not to raid Canada’s pharmacies to try and buy cheaper medicines.” “Our newspapers,” they wrote, “are filled every day with stories of patients struggling to get medicines they are prescribed because we have barely enough drug supply to meet our needs. Shortages of medications across all therapeutic types have been happening more and more frequently, and Canadian patients are endangered by them.”
In May 2004, anesthesiologist and American Medical Association trustee Rebecca J. Patchin, MD spoke before the Department of Health and Human Services Task Force on Drug Importation to express concern about the safety and reliability of imported drugs.